In a press release on December 10, 2009 Nattopharma announced the first use of MenaQ7, the natural vitamin K2, as an intervention in a placebo controlled clinical trial on dialysis patients. The aim of the study was to assess the effects of natural vitamin K2 on vascular health parameters in a patient group that has a very high degree of risk for cardiovascular disease.
News and Media
Article on the Effect of MenaQ7 Natural Vitamin K2 published by the American Journal of Kidney Disease
Positive results on “Clinical trial on beneficial effects of long term MenaQ7® intake by postmenopausal women”
In 2007 NattoPharma initiated a 3-year clinical intervention study on the effects of MenaQ7® on bone and cardiovascular health, respectively. Recruitment for the study started in early 2008 and the last measurements have been completed in the fall of 2011. The compliance was excellent - with 91.4% of the randomized participants staying in the study until its completion. The data are presently evaluated but already it may be concluded that the results are positive and that the primary efficacy parameters are met.
Don’t miss the opportunity to listen to Professor Cees Vermeer present the outcomes of the 3-year clinical trial investigating beneficial effects of natural vitamin K2 (MenaQ7) on bone and vascular health.
MenaQ7 is the first Vitamin K supplement with demonstrated health effects at nutritionally relevant doses.
For the Press
Director of Communications
(+1) 609-454-2992 x 220